AC
Accustem Sciences Inc.
ACUT · OTC
$0.16 +22.89% (+$0.03)
1M -11.43%
Market Cap $1.93M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.22
37.5% upside
Current Price
$0.16
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACUT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 19.60x
EV/EBITDA N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 1,680.03%
Op. margin 1,780.03%
FCF margin 1,224.39%
Quality
58 /100
Average ROA 102.92%
Asset turnover 0.06x
ROIC 43.20%
Debt
0 /100
High Current ratio 0.02x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
39 /100
Moderate EPS volatility 19.68%
Profitable years 0
Beta 1.87x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACUT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wendy E. Blosser
Employees
4
Headquarters
New York City